MIF-1
MIF-1 (Melanostatin), an endogenous brain peptide, is a potent dopamine receptor allosteric modulator. MIF-1 inhibits melanin formation. MIF-1 blocks the effects of opioid receptor activation to modulate the analgesic effects. MIF-1 accesses from the blood to the CNS by directly crossing the blood-brain barrier (BBB).
For research use only. We do not sell to patients.
- CAS No.: 2002-44-0
- Formula: C13H24N4O3
- Molecular Weight:284.35
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Dopamine Receptor Isoforms
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CCRF-CEM | IC50 |
2.6 μM
Compound: 1a
|
In vitro cytotoxic activity against CCRF-CEM human lymphoblastoid cells in culture.
In vitro cytotoxic activity against CCRF-CEM human lymphoblastoid cells in culture.
|
10.1016/0960-894X(96)00451-9 |
MIF-1 (Melanostatin, 1 μM) provokes a reversible hyperpolarization and a suppression of spontaneous action potentials[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MIF-1 (Melanostatin, 1 mg/kg; i.p.; daily, for 8 weeks; Sprague-Dawley rats) attenuates spiroperidol-induced impairment of development of striatal dopamine D2 receptors in rats[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Wistar rats[1]
-
Dosage:1 mg/kg
-
Administration:Intraperitoneal injection; once, for 1 hour
-
Result:Decreased the analgesic effect. Increased the pain threshold for at least 1 h.
-
Animal Model:Sprague-Dawley rats[3]
-
Dosage:1 mg/kg
-
Administration:Intraperitoneal injection; daily, for 8 weeks
-
Result:Attenuated the ontogenic impairment of striatal D2 receptors that was produced by spiroperidol (HY-B1371) treatment.
Chemical Information
-
CAS No. 2002-44-0
-
Molecular Weight 284.35
-
Formula C13H24N4O3
-
Synonyms
Pro-Leu-Gly-NH2; Melanostatin
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Bocheva A, et, al. Antiopioid properties of the TYR-MIF-1 family. Methods Find Exp Clin Pharmacol. 2004 Nov;26(9):673-7. [Content Brief]
[2]. Valentijn JA, et, al. Melanostatin (NPY) inhibited electrical activity in frog melanotrophs through modulation of K+, Na+ and Ca2+ currents. J Physiol. 1994 Mar 1;475(2):185-95. [Content Brief]
[3]. Saleh MI, et, al. MIF-1 attenuates spiroperidol alteration of striatal dopamine D2 receptor ontogeny. Peptides. 1989 Jan-Feb;10(1):35-9. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
MIF-1 Related Classifications
HY-107663 Related Classifications
Powered by Bioz